Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116875212 | 11687521 | 2 | F | 201411 | 20160804 | 20151030 | 20160812 | EXP | US-ABBVIE-15K-163-1395892-00 | ABBVIE | 61.80 | YR | F | Y | 39.04000 | KG | 20160812 | CN | COUNTRY NOT SPECIFIED | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116875212 | 11687521 | 1 | PS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | U | 1061170 | 125057 | 160 | MG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | ||||||
| 116875212 | 11687521 | 2 | SS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | U | 1061170 | 125057 | 40 | MG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | QOW | |||||
| 116875212 | 11687521 | 3 | SS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | U | 1061170 | 125057 | 40 | MG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | QOW | |||||
| 116875212 | 11687521 | 4 | C | TRAMADOL. | TRAMADOL | 1 | 0 | ||||||||||||
| 116875212 | 11687521 | 5 | C | BACLOFEN. | BACLOFEN | 1 | 0 | ||||||||||||
| 116875212 | 11687521 | 6 | C | MELOXICAM. | MELOXICAM | 1 | 0 | ||||||||||||
| 116875212 | 11687521 | 7 | C | LOPRESSOR | METOPROLOL TARTRATE | 1 | 0 | ||||||||||||
| 116875212 | 11687521 | 8 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | 0 | ||||||||||||
| 116875212 | 11687521 | 9 | C | PROZAC | FLUOXETINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 116875212 | 11687521 | 10 | C | FLOMAX | TAMSULOSIN HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 116875212 | 11687521 | 11 | C | NIFEDIPINE. | NIFEDIPINE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 116875212 | 11687521 | 1 | Crohn's disease |
| 116875212 | 11687521 | 4 | Back pain |
| 116875212 | 11687521 | 5 | Neck pain |
| 116875212 | 11687521 | 6 | Osteoarthritis |
| 116875212 | 11687521 | 7 | Hypertension |
| 116875212 | 11687521 | 8 | Gastrooesophageal reflux disease |
| 116875212 | 11687521 | 9 | Depression |
| 116875212 | 11687521 | 10 | Urinary incontinence |
| 116875212 | 11687521 | 11 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 116875212 | 11687521 | OT |
| 116875212 | 11687521 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 116875212 | 11687521 | Blister | |
| 116875212 | 11687521 | Blister infected | |
| 116875212 | 11687521 | Blister rupture | |
| 116875212 | 11687521 | Bursa disorder | |
| 116875212 | 11687521 | Bursitis | |
| 116875212 | 11687521 | Diarrhoea | |
| 116875212 | 11687521 | Dry skin | |
| 116875212 | 11687521 | Fall | |
| 116875212 | 11687521 | Impaired healing | |
| 116875212 | 11687521 | Lower limb fracture | |
| 116875212 | 11687521 | Patella fracture | |
| 116875212 | 11687521 | Scab | |
| 116875212 | 11687521 | Skin discolouration | |
| 116875212 | 11687521 | Skin wound | |
| 116875212 | 11687521 | Urinary retention | |
| 116875212 | 11687521 | Wound secretion |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 116875212 | 11687521 | 1 | 201312 | 201312 | 0 | |
| 116875212 | 11687521 | 2 | 201412 | 0 | ||
| 116875212 | 11687521 | 3 | 2015 | 0 |